3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Non-Muscle Invasive Bladder Neoplasms
4
Urinary Bladder Neoplasms
2
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Carcinoma in Situ
1
Interventions
dodecyl maltoside
2
Magnetic Resonance Imaging
2
Electrocardiography
2
Diphenhydramine
2
Acetaminophen
2
fludarabine phosphate
1
fludarabine
1
durvalumab
1
aldesleukin
1
Tomography, X-Ray Computed
1
Respiratory Function Tests
1
Prochlorperazine
1
Positron-Emission Tomography
1
Ondansetron
1
O(6)-codeine methyl ether
1
Meperidine
1
Mastectomy, Subcutaneous
1
Loperamide
1
Interleukin-2
1
Innovar
1
Indomethacin
1
Hydroxyzine
1
Histamine Antagonists
1
Granisetron
1
Droperidol
1
Doxylamine
1
Docetaxel
1
Diphenoxylate
1
Cystoscopy
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma in Situ
×
BCG Vaccine
×
90 days
×
Clear all
NCT06833073
2026-05-28
INTerpath-011
Merck Sharp & Dohme LLC
Phase 2
Recruiting
308 enrolled